Abstract
FDA-approved small-molecule inhibitors of EZH2 can indirectly target BZW2 and because BZW2 functions as an oncogene, these inhibitors could serve as therapeutic agents for colorectal cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have